HRP20050563A2

HRP20050563A2 - Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Methods for predicting therapeutic response to agents acting on the growth hormone receptor Download PDF

Info

Publication number: HRP20050563A2
Authority: HR; Croatia
Prior art keywords: subject; agent; allele; ghr; ghrd3
Prior art date: 2002-12-19

Application number

HR20050563A

Other languages

English (en)

Croatian (hr)

Inventor

Bougneres Pierre

Original Assignee

Pfizer Health Ab

Priority date

2002-12-19

Filing date

2005-06-16

Publication date

2005-12-31

2005-06-16 Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab

2005-12-31 Publication of HRP20050563A2 publication Critical patent/HRP20050563A2/hr

Links

102100020948 Growth hormone receptor Human genes 0.000 title claims description 320
238000000034 method Methods 0.000 title claims description 305
239000003795 chemical substances by application Substances 0.000 title claims description 157
108010068542 Somatotropin Receptors Proteins 0.000 title description 311
230000004797 therapeutic response Effects 0.000 title description 4
102000018997 Growth Hormone Human genes 0.000 claims description 227
108010051696 Growth Hormone Proteins 0.000 claims description 227
108090000623 proteins and genes Proteins 0.000 claims description 199
239000000122 growth hormone Substances 0.000 claims description 184
102000004169 proteins and genes Human genes 0.000 claims description 171
108090000765 processed proteins & peptides Proteins 0.000 claims description 165
108700028369 Alleles Proteins 0.000 claims description 158
102000004196 processed proteins & peptides Human genes 0.000 claims description 155
229920001184 polypeptide Polymers 0.000 claims description 147
230000004044 response Effects 0.000 claims description 126
238000011282 treatment Methods 0.000 claims description 98
150000007523 nucleic acids Chemical class 0.000 claims description 93
230000001965 increasing effect Effects 0.000 claims description 89
102000039446 nucleic acids Human genes 0.000 claims description 77
108020004707 nucleic acids Proteins 0.000 claims description 77
101150020003 GHR gene Proteins 0.000 claims description 67
230000027455 binding Effects 0.000 claims description 63
238000009739 binding Methods 0.000 claims description 62
230000003247 decreasing effect Effects 0.000 claims description 59
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
230000012010 growth Effects 0.000 claims description 34
206010000599 Acromegaly Diseases 0.000 claims description 25
208000008589 Obesity Diseases 0.000 claims description 24
235000020824 obesity Nutrition 0.000 claims description 24
206010028980 Neoplasm Diseases 0.000 claims description 23
201000011510 cancer Diseases 0.000 claims description 23
206010018265 Gigantism Diseases 0.000 claims description 22
208000020221 Short stature Diseases 0.000 claims description 22
238000012217 deletion Methods 0.000 claims description 22
230000037430 deletion Effects 0.000 claims description 22
208000035475 disorder Diseases 0.000 claims description 22
206010020772 Hypertension Diseases 0.000 claims description 21
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 21
208000001145 Metabolic Syndrome Diseases 0.000 claims description 21
208000019022 Mood disease Diseases 0.000 claims description 21
206010041277 Sodium retention Diseases 0.000 claims description 21
206010012601 diabetes mellitus Diseases 0.000 claims description 21
208000019622 heart disease Diseases 0.000 claims description 21
208000015181 infectious disease Diseases 0.000 claims description 21
230000036651 mood Effects 0.000 claims description 21
208000019116 sleep disease Diseases 0.000 claims description 21
229910052708 sodium Inorganic materials 0.000 claims description 21
239000011734 sodium Substances 0.000 claims description 21
208000024891 symptom Diseases 0.000 claims description 21
230000001983 lactogenic effect Effects 0.000 claims description 19
230000001195 anabolic effect Effects 0.000 claims description 18
230000002596 correlated effect Effects 0.000 claims description 18
230000001904 diabetogenic effect Effects 0.000 claims description 18
239000012634 fragment Substances 0.000 claims description 18
230000002366 lipolytic effect Effects 0.000 claims description 18
238000009396 hybridization Methods 0.000 claims description 16
238000002474 experimental method Methods 0.000 claims description 11
101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 8
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
230000002159 abnormal effect Effects 0.000 claims description 3
208000020685 sleep-wake disease Diseases 0.000 claims 2
235000018102 proteins Nutrition 0.000 description 166
150000001875 compounds Chemical class 0.000 description 158
210000004027 cell Anatomy 0.000 description 137
238000012360 testing method Methods 0.000 description 127
230000000694 effects Effects 0.000 description 109
108020004414 DNA Proteins 0.000 description 108
239000000523 sample Substances 0.000 description 95
239000003814 drug Substances 0.000 description 76
229940079593 drug Drugs 0.000 description 65
238000001514 detection method Methods 0.000 description 62
239000000203 mixture Substances 0.000 description 50
239000013615 primer Substances 0.000 description 49
230000002829 reductive effect Effects 0.000 description 48
239000013598 vector Substances 0.000 description 47
102000040430 polynucleotide Human genes 0.000 description 44
108091033319 polynucleotide Proteins 0.000 description 44
239000002157 polynucleotide Substances 0.000 description 44
241001465754 Metazoa Species 0.000 description 40
230000014509 gene expression Effects 0.000 description 40
238000003199 nucleic acid amplification method Methods 0.000 description 40
230000003321 amplification Effects 0.000 description 39
125000003729 nucleotide group Chemical group 0.000 description 39
108020004999 messenger RNA Proteins 0.000 description 38
239000002773 nucleotide Substances 0.000 description 38
108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
108010029485 Protein Isoforms Proteins 0.000 description 32
102000001708 Protein Isoforms Human genes 0.000 description 32
235000001014 amino acid Nutrition 0.000 description 31
229940024606 amino acid Drugs 0.000 description 30
238000003556 assay Methods 0.000 description 30
239000000047 product Substances 0.000 description 30
150000001413 amino acids Chemical class 0.000 description 29
239000013604 expression vector Substances 0.000 description 29
239000012472 biological sample Substances 0.000 description 26
239000000556 agonist Substances 0.000 description 25
229920000642 polymer Polymers 0.000 description 23
238000003752 polymerase chain reaction Methods 0.000 description 23
108010000521 Human Growth Hormone Proteins 0.000 description 22
102000002265 Human Growth Hormone Human genes 0.000 description 22
239000000854 Human Growth Hormone Substances 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 22
108091028043 Nucleic acid sequence Proteins 0.000 description 21
239000003153 chemical reaction reagent Substances 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 20
239000005557 antagonist Substances 0.000 description 19
238000005516 engineering process Methods 0.000 description 19
239000003446 ligand Substances 0.000 description 19
239000000463 material Substances 0.000 description 19
210000000287 oocyte Anatomy 0.000 description 19
108010033419 somatotropin-binding protein Proteins 0.000 description 19
241000894007 species Species 0.000 description 19
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
102400001066 Growth hormone-binding protein Human genes 0.000 description 17
125000003275 alpha amino acid group Chemical group 0.000 description 17
125000000539 amino acid group Chemical group 0.000 description 17
239000007787 solid Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
108700019146 Transgenes Proteins 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
239000000833 heterodimer Substances 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 16
239000000126 substance Substances 0.000 description 16
230000009261 transgenic effect Effects 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
229940088598 enzyme Drugs 0.000 description 15
238000009472 formulation Methods 0.000 description 15
239000003112 inhibitor Substances 0.000 description 15
239000003550 marker Substances 0.000 description 15
239000012528 membrane Substances 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
102000053602 DNA Human genes 0.000 description 14
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
210000004408 hybridoma Anatomy 0.000 description 14
230000037361 pathway Effects 0.000 description 14
229920001223 polyethylene glycol Polymers 0.000 description 14
206010053759 Growth retardation Diseases 0.000 description 13
241000124008 Mammalia Species 0.000 description 13
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 12
201000010099 disease Diseases 0.000 description 12
208000030941 fetal growth restriction Diseases 0.000 description 12
-1 for example Polymers 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
239000002987 primer (paints) Substances 0.000 description 12
230000000295 complement effect Effects 0.000 description 11
230000004927 fusion Effects 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
230000006801 homologous recombination Effects 0.000 description 10
238000002744 homologous recombination Methods 0.000 description 10
230000008569 process Effects 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000001488 sodium phosphate Substances 0.000 description 10
206010035226 Plasma cell myeloma Diseases 0.000 description 9
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
201000004224 Schnyder corneal dystrophy Diseases 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000011616 biotin Substances 0.000 description 9
229960002685 biotin Drugs 0.000 description 9
235000020958 biotin Nutrition 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002372 labelling Methods 0.000 description 9
201000000050 myeloid neoplasm Diseases 0.000 description 9
239000007790 solid phase Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
238000005406 washing Methods 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 8
238000002965 ELISA Methods 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
241000269370 Xenopus <genus> Species 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000003491 array Methods 0.000 description 8
239000012707 chemical precursor Substances 0.000 description 8
238000011161 development Methods 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
230000000670 limiting effect Effects 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
230000035772 mutation Effects 0.000 description 8
238000003259 recombinant expression Methods 0.000 description 8
229910000162 sodium phosphate Inorganic materials 0.000 description 8
235000011008 sodium phosphates Nutrition 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 8
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
102100034343 Integrase Human genes 0.000 description 7
241000269368 Xenopus laevis Species 0.000 description 7
230000006870 function Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000012216 screening Methods 0.000 description 7
238000007423 screening assay Methods 0.000 description 7
230000019491 signal transduction Effects 0.000 description 7
229960004532 somatropin Drugs 0.000 description 7
238000010561 standard procedure Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 6
239000011324 bead Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000000423 cell based assay Methods 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
108010005905 delta-hGHR Proteins 0.000 description 6
238000002405 diagnostic procedure Methods 0.000 description 6
102000018358 immunoglobulin Human genes 0.000 description 6
108700037519 pegvisomant Proteins 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
238000000926 separation method Methods 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
JBMAUZQHVVHPEL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzenesulfonic acid Chemical compound OC1=CC=C(S(O)(=O)=O)C=C1[N+]([O-])=O JBMAUZQHVVHPEL-UHFFFAOYSA-N 0.000 description 5
108700024394 Exon Proteins 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
101100448391 Homo sapiens GHR gene Proteins 0.000 description 5
241001529936 Murinae Species 0.000 description 5
241001494479 Pecora Species 0.000 description 5
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
108010091086 Recombinases Proteins 0.000 description 5
102000018120 Recombinases Human genes 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
108010090804 Streptavidin Proteins 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
239000013068 control sample Substances 0.000 description 5
230000002950 deficient Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
229960002995 pegvisomant Drugs 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 5
230000004952 protein activity Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000001262 western blot Methods 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
206010056438 Growth hormone deficiency Diseases 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
101710203526 Integrase Proteins 0.000 description 4
108091092195 Intron Proteins 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000006471 dimerization reaction Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
229920001519 homopolymer Polymers 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
210000001161 mammalian embryo Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
210000001236 prokaryotic cell Anatomy 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
108700031632 somatrem Proteins 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
238000001890 transfection Methods 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
208000006302 Laron syndrome Diseases 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
108020004711 Nucleic Acid Probes Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
239000013614 RNA sample Substances 0.000 description 3
108020003564 Retroelements Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000013461 design Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000012636 effector Substances 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000003205 genotyping method Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000003100 immobilizing effect Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000011901 isothermal amplification Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000006011 modification reaction Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000002853 nucleic acid probe Substances 0.000 description 3
238000002823 phage display Methods 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
208000016857 Growth hormone insensitivity syndrome Diseases 0.000 description 2
101710099093 Growth hormone receptor Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108091027974 Mature messenger RNA Proteins 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229960003896 aminopterin Drugs 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
108010074605 gamma-Globulins Proteins 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
201000008980 hyperinsulinism Diseases 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
238000002966 oligonucleotide array Methods 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
230000002974 pharmacogenomic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
229960003259 somatrem Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
208000013558 Developmental Bone disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000702191 Escherichia virus P1 Species 0.000 description 1
108010046276 FLP recombinase Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
208000001362 Fetal Growth Retardation Diseases 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010016807 Fluid retention Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
206010070531 Foetal growth restriction Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 description 1
101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000713887 Human endogenous retrovirus Species 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
108010013127 Met-human growth hormone Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001296119 Panteles Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
206010041092 Small for dates baby Diseases 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000026928 Turner syndrome Diseases 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
ABIUHPWEYMSGSR-UHFFFAOYSA-N bromocresol purple Chemical compound BrC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Br)C(O)=C(C)C=2)=C1 ABIUHPWEYMSGSR-UHFFFAOYSA-N 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
229940121657 clinical drug Drugs 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011437 continuous method Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
230000009274 differential gene expression Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000010072 hypochondroplasia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000013115 immunohistochemical detection Methods 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000012514 monoclonal antibody product Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
UPXAZUFKXWLNMF-UHFFFAOYSA-N n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=N UPXAZUFKXWLNMF-UHFFFAOYSA-N 0.000 description 1
ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
230000000720 neurosecretory effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005580 one pot reaction Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000004816 paper chromatography Methods 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002294 pubertal effect Effects 0.000 description 1
238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000033300 receptor internalization Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
230000003093 somatogenic effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000001429 visible spectrum Methods 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000007794 visualization technique Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1